Table 5. . Antimelanoma therapy pre- and post-dendritic cell vaccine.
| Other therapies received | Stage 3 NMD (n = 18) | Stage 4 NMD (n = 30) | Stage 4 MD (n = 24) | |||
|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | |
| Metastasectomy (ies) locoregional | 18 | 3 | 2 | 1 | 9 | 2 |
| Metastasectomy (ies) distant | 0 | 6 | 23 | 17 | 11 | 7 |
| RT (not brain) | 7 | 4 | 6 | 6 | 7 | 6 |
| Brain RT | 0 | 2 | 6 | 5 | 7 | 8 |
| Chemotherapy | 8 | 4 | 14 | 7 | 19 | 16 |
| IL-2 | 6 | 2 | 15 | 7 | 13 | 2 |
| IFN-α | 9 | 1 | 10 | 1 | 11 | 1 |
| GM-CSF | 5 | 3 | 11 | 4 | 8 | 1 |
| Anti-VEGF | 0 | 1 | 1 | 1 | 4 | 2 |
| Anti-VEGF-TKI | 0 | 0 | 0 | 0 | 1 | 4 |
| Vaccine | 2 | 2 | 7 | 3 | 0 | 1 |
| Anti-BRAF | 0 | 0 | 0 | 2 | 0 | 1 |
| Anti-BRAF + Anti-MEK | 0 | 0 | 0 | 0 | 0 | 1 |
| Anti-CTLA4 | 0 | 0 | 0 | 4 | 1 | 5 |
| Anti-PD1 | 0 | 0 | 0 | 1 | 0 | 0 |
| None and no PD | 0 | 6 | 0 | 3 | 0 | 2 |
CSF: Cerebrospinal fluid; LR: Locoregional; MD: Measurable disease; NMD: No measurable disease; PD: Progressive disease; PD1: Programmed death molecule 1; RT: Radiation therapy; TKI: Tyrosine kinase inhibitor.